Alnylam Pharmaceuticals Inc (ALNY)vsCardio Diagnostics Holdings Inc (CDIO)
ALNY
Alnylam Pharmaceuticals Inc
$286.62
-0.62%
HEALTHCARE · Cap: $35.71B
CDIO
Cardio Diagnostics Holdings Inc
$1.58
+1.28%
HEALTHCARE · Cap: $4.82M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 25887116% more annual revenue ($4.29B vs $16,560). ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
CDIO
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.2%
Fair Value
$2337.47
Current Price
$286.62
$2050.85 discount
Margin of Safety
+50.0%
Fair Value
$2.64
Current Price
$1.58
$1.06 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Reasonable price relative to book value
Revenue surging 185.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 35.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.49 suggests the stock is reasonably priced for its growth.
Bull Case : CDIO
The strongest argument for CDIO centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 185.1% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 67.0x leaves little room for execution misses.
Bear Case : CDIO
The primary concerns for CDIO are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ALNY profiles as a growth stock while CDIO is a hypergrowth play — different risk/reward profiles.
CDIO carries more volatility with a beta of 2.18 — expect wider price swings.
CDIO is growing revenue faster at 185.1% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 33/100) and 96.4% revenue growth. CDIO offers better value entry with a 50.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Cardio Diagnostics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cardio Diagnostics Holdings Inc (CDIO) is an innovative biotechnology company dedicated to improving cardiovascular health through advanced diagnostic solutions. By harnessing cutting-edge technology, CDIO provides healthcare professionals with essential tools for accurate assessment and effective management of cardiovascular diseases, ultimately enhancing patient outcomes. With a strong focus on personalized medicine, the company is strategically poised for substantial growth, representing a compelling investment opportunity for institutional investors aiming to leverage advancements in the evolving healthcare landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?